Qingcheng New Drug-B (02396.HK) announced its interim results, reporting a loss of 122 million yuan during the period, an increase of 40.65% year-on-year.

Zhizhong Finance APP News, Qingcheng New Medicine-B (02396.HK) announced its interim results for the six months ended June 30, 2026. The group's other income and gains amounted to RMB 999,000, an increase of 59.08% year-on-year; the loss attributable to equity holders of the parent company was RMB 122 million, an increase of 40.65% year-on-year; basic and diluted loss per share was RMB 1.04; an interim dividend of HKD 0.50 per share is proposed.